This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Urosevic, M. Articles by Dummer, R. Search for Related Content PubMed PubMed Citation Articles by Urosevic, M. Articles by Dummer, R.

Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor

A Novel Tumor Antigen Induced by Interferon-?

¹ Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; ² 3M Pharmaceuticals, St. Paul, Minnesota; and ³ 3M Pharmaceuticals, Neuss, Germany

ABSTRACT

Purpose: Imiquimod represents a synthetic local immune response modifier that has demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-.

Experimental Design: To more closely define and elucidate mechanisms leading to basal cell carcinoma clearance in vivo, we examined gene expression profiles of skin basal cell carcinoma before and after treatment with 5% imiquimod cream (Aldara) by using high-density oligonucleotide arrays.

Results: We show that imiquimod predominantly induces genes involved in different aspects of immune response. In addition to effects on immunity, imiquimod treatment modulates the expression of genes involved in the control of apoptosis and oncogenesis. Array data indicated that imiquimod treatment induces expression of opioid growth factor receptor, a molecule recently reported to be a target for antitumor antibody responses. Immunohistochemistry revealed in vivo up-regulation of opioid growth factor receptor protein on tumor and on infiltrating cells after treatment. By using basal cell carcinoma cell lines treated with IFN- or imiquimod, we show that opioid growth factor receptor up-regulation is IFN--mediated, rather then directly imiquimod-mediated. By using tissue microarray containing 52 basal cell carcinomas, we demonstrate opioid growth factor receptor expression in almost half of the cases. Expression of opioid growth factor receptor correlated with a longer recurrence-free period in basal cell carcinoma that recurred after radiotherapy (Kaplan-Meier analysis, P = 0.041).

Conclusions: In addition to its immunomodulatory and antiproliferative activity, opioid growth factor receptor seems to have a prognostic significance in basal cell carcinoma patients. Our data add to the growing list of basal cell carcinoma-associated tumor antigens.

This article has been cited by other articles:

				I. S. Zagon, R. N. Donahue, M. Rogosnitzky, and P. J. Mclaughlin Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function Experimental Biology and Medicine, August 1, 2008; 233(8): 968 - 979. [Abstract] [Full Text] [PDF]

				M. Urosevic, R. Dummer, C. Conrad, M. Beyeler, E. Laine, G. Burg, and M. Gilliet Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment J Natl Cancer Inst, August 3, 2005; 97(15): 1143 - 1153. [Abstract] [Full Text] [PDF]